ASLN — Aslan Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $0.13m
- -$2.36m
Annual cashflow statement for Aslan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -42.2 | -46.7 | -17 | -31.6 | -51.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.01 | 24.2 | 1.72 | 1.43 | 5.64 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.45 | -3.78 | -0.099 | -4.12 | 6.91 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -39.5 | -25.8 | -15.1 | -34 | -38.4 |
| Capital Expenditures | -0.08 | -0.003 | -0.005 | -0.036 | -0.027 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -23 | 0.008 | 0.006 | 0.008 | 0.442 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -23.1 | 0.005 | 0.001 | -0.028 | 0.415 |
| Financing Cash Flow Items | -5.39 | 1.33 | -0.229 | -4.58 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 40.9 | 19.1 | 7.17 | 110 | 4.72 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -21.7 | -6.71 | -7.88 | 75.8 | -33.3 |